Novo Nordisk

Pharmaceuticals
NVO
$ 106 3
Share price
$ 244 bn
Market Cap
$ 265 bn
Enterprise Value

Carbon footprint

0.35 Ton
GHG emissions per $ 1 mln investment
0.01x the weighted average for S&P 500
FY2021
How is this calculated?
+3.3%
YOY change in GHG emissions
Weaker than the -8.7% weighted average for S&P 500
FY2021 vs. previous year

Primary Climate Goal

-11%
Proj. YOY change in GHG emissions (Scope 1 + 2)
Stronger than the -5.1% weighted average for S&P 500
FY2022
How is this calculated?

Novo Nordisk aims to achieve net zero for Scope 1 + 2 by 2030


1.5°C
Novo Nordisk's actual and proj. GHG emissions (Scope 1 + 2) (Kt of CO2e)

GHG emissions and Carbon intensity

Novo Nordisk's GHG emissions (market-based) (Kt of CO2e)
Novo Nordisk's Carbon intensity (Tons per 1 USDm)

Novo Nordisk's carbon footprint

Novo Nordisk reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2021 at 93 Kt (+3/+3.3% y-o-y). At the sime time, carbon intensity was down at 4.1 t (-0.4 /-8.9% y-o-y).

Novo Nordisk's Scope 3 emissions declined to 1,449 Kt (-62 /-4.1% y-o-y). The performance has been erratic recently.

The company is committed to achieving net zero for Scope 1 + 2 by 2030, which translates into the estimated reduction of -10 Kt per annum over the period of FY2022 - FY2030. This science-based target is aligned with Paris Agreement to limit global warming to 1.5°C above pre-industrial levels.

Company environmental metrics

Show more...